[Activity and safety of fenspiride in bronchial hyperexudation (author's transl)].
This clinical trial of fenspiride (injectable and sustained-release 80 mg tablet) was carried out on patients selected because their bronchopathy was of a hypersecretory type. Interesting results were observed in 20 out of 37 cases, but they were often delayed. This group of patients included a high proportion of patients with major hypersecretion; the efficacy of fenspiride is often evident, (in 8 out of 11 cases) but it is unpredictable individually. It can be concluded from this trial that a long term treatment with fenspiride, well tolerated, can usefully be tried in patients with predominant signs of bronchial hyperexudation.
D000328:Adult; D000368:Aged; D001980:Bronchi / Q000187:drug effects / Q000378:metabolism*; D001982:Bronchial Diseases / Q000188:drug therapy*; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013183:Sputum / Q000187:drug effects; D013997:Time Factors
D013141:Spiro Compounds
Efficacité-tolérance du fenspiride dans les hyper-exsudations bronchiques.